Status:
COMPLETED
Prebiotics in the Parkinson's Disease Microbiome
Lead Sponsor:
Rush University Medical Center
Conditions:
Parkinson Disease
Eligibility:
All Genders
Phase:
NA
Brief Summary
There are about one million Parkinson's disease (PD) patients in America. The risks associated with whether or not an individual may develop PD include environment and genetic (biologic, hereditary) f...
Detailed Description
Intestinal microbiota, are a dynamic community of commensal bacteria that modulate gut homeostasis and systemic biological processes including brain development and function through a bidirectional "G...
Eligibility Criteria
Inclusion
- Clinical diagnosis of Parkinson's disease,
- \>age 30,
- Must be able to consent
Exclusion
- prior intestinal resection,
- patient history of GI diseases except for hiatal hernia, gastroesophageal reflux disease, hemorrhoids,
- severe renal disease defined by creatinine more than 2 ½ times normal,
- markedly abnormal liver function defined by liver function tests over 4 times normal levels or elevated bilirubin,
- antibiotic use within the last 12 weeks prior to enrollment,
- a plan to have a major change in dietary habit during the study,
- consumption of probiotics, prebiotics or synbiotics without an appropriate 2 week washout period
Key Trial Info
Start Date :
August 31 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2022
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04512599
Start Date
August 31 2020
End Date
March 31 2022
Last Update
November 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rush University Medical Cener
Chicago, Illinois, United States, 60612